| Name | Title | Contact Details |
|---|
The Ohio Willow Wood Company is a Mount Sterling, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sroufe Healthcare Products, LLC is a leading manufacturer and worldwide supplier of cast boots, post-op shoes, orthopedic softgoods and accessories. Founded in 1975, Sroufe pioneered the use of lean and cell manufacturing techniques to establish an
Headquartered in Santa Barbara, California, Sientra offers leading transformative treatments and technologies focused on progressing the art of plastic surgery and making a difference in patients` lives. With unrivaled safety, state-of-the-art science and exceptional service; paired with unparalleled partnerships with plastic surgeons, the Sientra portfolio of proprietary innovations radically advances how plastic surgeons think, work and care for their patients. The company`s core breast products segment includes its state-of-the-art Sientra breast implants and its ground-breaking dual-port breast tissue expander, AlloX2® . In addition, the Sientra portfolio also includes BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*) and miraDry, the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Canadian Agency for Drugs and Technologies is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.